Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
Gastric
Advertisement
We recently spoke with expert clinicians about the rapidly changing treatment landscape in upper gastrointestinal cancers.
Circulating tumor DNA burden in patients with gastric cancer may aid oncologists in determining treatment options.
Dr. Cytryn considers two studies evaluating PD-1 inhibition in patients with MSI-high tumors in the locally advanced setting.
Dr. Janjigian reviews KEYNOTE-811, and how it led to the FDA approval of pembrolizumab for HER2-positive gastric cancers.
Of subtypes in KEYNOTE-059 and -061, HRD scores and TMB were highest in CIN and MSI-H subtypes, respectively.
Pembrolizumab previously received accelerated approval for this indication in 2021 based on interim results from KEYNOTE-811.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Dr. Cytryn shares insights on the implications of recent data from the DESTINY-Gastric04 and MATTERHORN trials.
Dr. Albiges shares her thoughts on the FDA approval of subcutaneous nivo in gastric cancer and how it will impact practice.
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
Roundtables
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
Video Insights
Advertisement
Section Editor
Samuel Cytryn, MDGastrointestinal Medical Oncologist | Memorial Sloan Kettering Cancer Center
Advertisement
Latest GI Oncology News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.